Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1217384.RA2gup5DgOq60_4cDA1t-KPn81K83btR-iFv4d_rnvx5Y130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1217384.RA2gup5DgOq60_4cDA1t-KPn81K83btR-iFv4d_rnvx5Y130_assertion type Assertion NP1217384.RA2gup5DgOq60_4cDA1t-KPn81K83btR-iFv4d_rnvx5Y130_head.
- NP1217384.RA2gup5DgOq60_4cDA1t-KPn81K83btR-iFv4d_rnvx5Y130_assertion description "[In vivo, ALK regulated VEGFA production and tumor angiogenesis in ALCL and NSCLC, and the treatment with the anti-VEGFA antibody bevacizumab strongly impaired ALCL growth in mouse xenografts.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217384.RA2gup5DgOq60_4cDA1t-KPn81K83btR-iFv4d_rnvx5Y130_provenance.
- NP1217384.RA2gup5DgOq60_4cDA1t-KPn81K83btR-iFv4d_rnvx5Y130_assertion evidence source_evidence_literature NP1217384.RA2gup5DgOq60_4cDA1t-KPn81K83btR-iFv4d_rnvx5Y130_provenance.
- NP1217384.RA2gup5DgOq60_4cDA1t-KPn81K83btR-iFv4d_rnvx5Y130_assertion SIO_000772 25193384 NP1217384.RA2gup5DgOq60_4cDA1t-KPn81K83btR-iFv4d_rnvx5Y130_provenance.
- NP1217384.RA2gup5DgOq60_4cDA1t-KPn81K83btR-iFv4d_rnvx5Y130_assertion wasDerivedFrom befree-2016 NP1217384.RA2gup5DgOq60_4cDA1t-KPn81K83btR-iFv4d_rnvx5Y130_provenance.
- NP1217384.RA2gup5DgOq60_4cDA1t-KPn81K83btR-iFv4d_rnvx5Y130_assertion wasGeneratedBy ECO_0000203 NP1217384.RA2gup5DgOq60_4cDA1t-KPn81K83btR-iFv4d_rnvx5Y130_provenance.